BEVERLY, Mass. and TORONTO, June 21, 2017 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced a scholarship program to support MedTech For Solution’s OvaTools Andrology and Embryology Training Institute in Fort Lauderdale, FL.
David Wolf, President and Chief Executive Officer stated, “We are pleased to offer the educational support that will allow the next generation of clinical embryologists to gain the theoretical and practical skills needed to excel in their field. The OvaTools program is synergistic with Hamilton Thorne’s goal of establishing standardization and best practices in the IVF lab that result in superior outcomes.”
Scholarship applicants will be asked to submit an essay on a topic relevant to the ART community. The top four essay submissions, as decided by the OvaTools’ staff, will be presented with awards. The essayist taking top honors will receive the $2,000 Hamilton Award. In addition, one Spencer Award ($1,000) and two Maxwell Awards ($500 each) will be a presented. The scholarship essay contest will be held twice a year.
“We greatly value the support Hamilton Thorne will provide at our grand opening symposium and the educational awards for our future training,” added Dr. Kathleen A. Miller, D.H.Sc., MedTech’s Vice President of Laboratory Services. “Hamilton Thorne is one of the most trusted suppliers of precision instruments, consumables, software and services to In Vitro Fertilization labs worldwide and we are proud to have them as a partner.”
Information on applying for the Hamilton Thorne sponsored scholarship, including applicant obligations, can be found at Scholarship Instructions or Application. Registration is now open for the July 8-10 Grand Opening Symposium and subsequent OvaTools training modules. The sessions will take place in Fort Lauderdale, FL.
About Hamilton Thorne Ltd. (https://www.hamiltonthorne.com)
Hamilton Thorne is a leading world-wide provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Its image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields. Hamilton Thorne’s standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics.
About MedTech For Solutions (https://medtech4solutions.com)
MedTech For Solutions offers a full range of services to specialty medical practices, with emphasis on ART/IVF practices and laboratories. The MT Laboratory Solutions Division is dedicated to working with practices in the building of new laboratories, as well as, improving clinical outcomes of existing facilities by establishing and implementing state-of-the-art embryology and andrology practices and optimizing ART/IVF laboratory operations. MedTech's Group Purchasing Organization (GPO) provides practices with significant savings for all medical, pharmacy, laboratory, capital equipment and office purchasing needs. Additionally, MedTech offers practice development, recruitment and risk management services.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict including the risk that the Company may not be able to obtain the necessary regulatory approvals, as applicable. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.